Gilead (GILD) Gears Up to Report Q1 Earnings: What to Expect? [Yahoo! Finance]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance
Gilead Sciences, Inc. Price, Consensus and EPS Surprise Gilead Sciences, Inc. price-consensus-eps-surprise-chart | Gilead Sciences, Inc. Quote Factors to Note Gilead has a market-leading HIV franchise, led by flagship HIV therapies — Biktarvy and Descovy. However, revenues in the first quarter might have been impacted by a decline in HIV franchise sales. The first quarter is typically impacted by the reset of patient copays and deductibles. In addition, inventory build-up in the fourth quarter leads to notable draw-downs by wholesalers in the first quarter, thereby impacting revenues. Gilead expects a 10-12% decline in HIV sales in the first quarter of 2024. While market share gains and continued double-digit growth in demand for HIV prevention for Biktarvy drove sales in 2023, Biktarvy missed the consensus mark in the fourth quarter of 2023. The trend is likely to have continued in the first quarter. Descovy's revenues, too, missed the consensus estimate in the previous quar
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Forbes Has Listed Gilead as One of America's Best Employers for Diversity [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Maxim Group from $90.00 to $85.00. They now have a "buy" rating on the stock.MarketBeat
- Gilead Sciences to Present at Upcoming Investor ConferencesBusiness Wire
- Gilead Sciences, Inc. (NASDAQ:GILD) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences, Inc. (NASDAQ: GILD) had its price target lowered by analysts at Barclays PLC from $80.00 to $76.00. They now have an "equal weight" rating on the stock.MarketBeat
GILD
Earnings
- 4/25/24 - Beat
GILD
Sec Filings
- 4/26/24 - Form 4
- 4/25/24 - Form 8-K
- 4/2/24 - Form 4
- GILD's page on the SEC website